Ezetimibe/atorvastatin

Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet.[1] It has also been approved to reduce elevated total cholesterol and elevated LDL in patients diagnosed with homozygous familial hypercholesterolemia as an adjunctive treatment to other hyperlipidemia treatments.[2]

Ezetimibe/atorvastatin
Combination of
EzetimibeHypolipidemic agent
AtorvastatinStatin
Clinical data
Trade namesLiptruzet, Atozet
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
Identifiers
PubChem CID
KEGG

Some cardiologists opposed the approval, because the combination reduced LDL cholesterol in a clinical trial, but it did not reduce heart disease. A clinical trial studying the endpoints of heart attacks, strokes and heart-related deaths is scheduled to conclude in 2014.[3]

Liptruzet was withdrawn from sale by its manufacturer in June 2015, but not for reasons of safety or effectiveness.[4]

Mechanism of action

This combination drug works to reduce cholesterol levels through two different pathways. The ezetimibe component of the medication works by inhibiting cholesterol absorption from food while the atorvastatin component inhibits intrinsic cholesterol production in the liver.[5]

Safety
  • The drug is not safe to use in patients with active liver disease or unexplained persistent elevations in hepatic transaminase.
  • Women that are pregnant or may become pregnant should not use the drug. It is a teratogenic agent that may disrupt the growth and development of a fetus. Immediate discontinuation is recommended in patients that become pregnant while taking this drug.

Adverse effects

Commonly reported adverse effects include:[6]

  • Musculoskeletal pain
  • Elevated liver enzymes (AST and ALT)
  • Gastrointestinal problems such as abdominal pain and nausea

See also

References
  1. "FDA Approves Merck's LIPTRUZET (ezetimibe and atorvastatin), a New Product That Can Help Powerfully Lower LDL Cholesterol". Business Wire. May 6, 2013. Retrieved May 6, 2013.
  2. "Liptruzet." CenterWatch. Web. 28 Oct. 2014.
  3. Drug to Cut Cholesterol Is Approved by the F.D.A. By Katie Thomas, New York Times, May 3, 2013
  4. Determination That LIPTRUZET (Ezetimibe and Atorvastatin) Tablets, 10 Milligrams/10 Milligrams, 10 Milligrams/20 Milligrams, 10 Milligrams/40 Milligrams, and 10 Milligrams/80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness Federal Register: Notice by the Food and Drug Administration on 11/20/2015.
  5. Liptruzet [package insert]. Whitehouse Station, NJ: Merck & Co.; 2013
  6. Clinical trial number NCT00418834 for "Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.